论文部分内容阅读
目的研究孟鲁司特对儿童支气管哮喘的临床疗效、肺功能及炎症因子水平的影响。方法选择2014年9月—2016年3月在铜川市妇幼保健院进行诊治的支气管哮喘患儿124例,随机分为观察组与对照组,每组62例。对照组给予常规吸入激素治疗,观察组在对照组基础上加用孟鲁司特钠咀嚼片。治疗3个月后,观察两组的疗效,进行日夜间症状评分,用酶联免疫吸附法测定血清中白介素(IL)-6、IL-8、核转录因子κB(NF-κB)的水平,用肺功能测试仪检测肺功能。结果观察组的有效率为88.71%,明显高于对照组的62.90%(P<0.05);治疗后,两组患儿的日夜间症状评分均明显降低(P<0.05),且观察组降低更为明显(P<0.05);治疗后,两组患儿的呼气流量峰值(PEF)、一秒钟用力呼气量(FEV1)、50%肺活量最大呼气流速(V50)与25%肺活量最大呼气流速(V25)均明显升高(P<0.05),且观察组升高更为明显(P<0.05);治疗后,两组患儿的IL-6、IL-8、NF-κB水平均明显降低(P<0.05),且观察组降低更为明显(P<0.05)。结论孟鲁司特对儿童支气管哮喘具有较好的临床疗效,能明显改善患儿的日夜间症状和肺功能,并降低IL-6、IL-8、NF-κB水平。
Objective To study the clinical effects of montelukast on children with bronchial asthma, pulmonary function and inflammatory cytokines levels. Methods 124 patients with bronchial asthma diagnosed and treated in Tongchuan MCH Hospital from September 2014 to March 2016 were randomly divided into observation group and control group with 62 cases in each group. Control group was given conventional inhaled hormone therapy, the observation group in the control group based on the use of montelukast sodium chewable tablets. Three months after the treatment, the curative effect of the two groups was observed, and the symptom scores of day and night were observed. The level of interleukin (IL) -6, IL-8 and NF-κB in serum were detected by enzyme-linked immunosorbent assay Pulmonary function test instrument to detect lung function. Results The effective rate of the observation group was 88.71%, which was significantly higher than that of the control group (62.90%, P <0.05). After treatment, the daytime and nighttime symptom scores of both groups were significantly decreased (P <0.05) (P <0.05). After treatment, peak expiratory flow (PEF), forced expiratory volume per second (FEV1), maximum expiratory flow rate (V50) of 50% and maximum vital capacity of 25% The levels of IL-6, IL-8 and NF-κB in the two groups were significantly higher than those in the control group (P <0.05) (P <0.05), and the decrease of the observation group was more obvious (P <0.05). Conclusion Montelukast has good clinical efficacy in children with bronchial asthma, can significantly improve children’s day and night symptoms and lung function, and reduce IL-6, IL-8, NF-κB levels.